Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Elicio Therapeutics (ELTX) Equity Average (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Equity Average readings, the most recent being $12.3 million for Q4 2023.

  • On a quarterly basis, Equity Average rose 112.46% to $12.3 million in Q4 2023 year-over-year; TTM through Dec 2023 was $12.3 million, a 112.46% increase, with the full-year FY2023 number at -$45.4 million, up 48.62% from a year prior.
  • Equity Average hit $12.3 million in Q4 2023 for Elicio Therapeutics, down from $18.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $84.8 million in Q2 2021 to a low of -$106.0 million in Q1 2023.
  • Median Equity Average over the past 4 years was -$43.2 million (2023), compared with a mean of -$32.9 million.
  • Biggest five-year swings in Equity Average: soared 312.64% in 2021 and later plummeted 7922.07% in 2022.
  • Elicio Therapeutics' Equity Average stood at -$76.8 million in 2020, then skyrocketed by 93.48% to -$5.0 million in 2021, then plummeted by 1874.08% to -$98.9 million in 2022, then skyrocketed by 112.46% to $12.3 million in 2023.
  • The last three reported values for Equity Average were $12.3 million (Q4 2023), $18.4 million (Q3 2023), and -$43.2 million (Q2 2023) per Business Quant data.